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inactivated tumour-suppressor genes This may lead to
uncontrolled cell division and rnahgnant transformanon
An increasing number of epidemiological studies Support the
Fathalla hypothesis Fathalla noted that pregnancy suppresses
ovulanon and protects against ovanan cancer The protecnve effect
increases with increasing panty Oral contraception inhibits
ovulauon and is also associated with decreased nsk of ovanan
cancer 4 This reducüon is related to the length of use of oral
contraception Furthermore the incidence of ovanan cancer peaks
after the menopause and complenon of maximum ovulatory cychcal
damage Cruickshank5 has predicted that because ovulanon occurs
more often in the nght ovary, one might txpect ovanan cancer to
developmorecommonlyonthenghtside Inastudyofwomenwith
epithehal ovanan cancer in Scotland, he found this to be so, with
more tumours in the nght ovary than the left5
In an independent review of nsk factors Pike6 stated that the
major impetus to cell replication is repair of the epithehal surface
after ovulanon He noted that each month cells divide to seal the
hole and added, "not that cell division itself causes cancer, but
whatever does is made worse by cell division" Henderson and
Preston-Marnn7 noted that the division of cells that would usually
not be rephcating may be especially error prone because efficient
repair mechamsms are absent Epidemiological evidence thus
pomts to defecnve cellular repair after ovulanon äs a major nsk
factor in ovanan cancer The molecular evidence suggests that this
may be attnbutable to inactivated tumour-suppressor genes,
possibly the missing link in the Fathalla hypothesis
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Mortality related to thrombosis in
congenital antithrombin IM deficiency
SIR,—Dr De Stefane and Dr Leone (Apnl 6, p 847) comment on
the results of our study on mortality in famihes with hereditary
antithrombin III (AT III) defiaency (Feb 2, p 260), and discuss
their own analysis of 37 famihes taken mamly from previously
pubhshed accounts Whereas we found no excess mortality
compared with the general populaüon in 171 family members from
10 kindreds, their findings in 552 individuals with a high probability
of defiaency were strongly suggestive of excess mortality from
venous thromboembohsm, although a direct companson with the
general populaüon was not possible They speculate äs to whether
our findings might have been related to the inclusion of kindreds
with mild climcal expression, and suggest that the use of
anncoagulants äs long-term prophylaxis in symptom-free
individuals should be reconsidered
We believe that our approach is more likely to lead to a correct
esumate of mortality in those with AT III deficiency than the
method descnbed by De Stefano and Leone because their
conclusions were based on 34 pedigrees from pubhshed reports and
3 pedigrees from their own senes As they point out, case-reports are
likely to give a biased view, since pedigrees with remarkable feamres
tend to be pubhshed We do not know if these reports gave complete
pedigrees that were confirmed by genealogical investigations
Moreover, we do not believe that there may be two populanons of
AT-III-defiaent kindreds, one with a high nsk of (fatal)
thromboembolism and one wim a low nsk Although, in retrospect,
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Mortality according to family pedigree
some famihes seem to have expenenced more episodes of
thromboembohsm than other famihes, this observanon per se does
not imply that one can predict a higher nsk for individuals from
these kindreds For type I defiaency, in which AT III acüvmes are
closely distnbuted around 50% of normal, differences in chmcal
seventy are hard to imagine, unless one suggests a second hentable
defect At present, there is no evidence for a second defect
With such reasomng m mind, we have repeated our analysis for
the ten famihes separately (figure) Although some vanation
between famihes is present, we believe that this is probably because
of chance vanation, and not because of true differences m mortality
assoaated with AT III defiaency In the three largest pedigrees, in
which the most rehable esumates would be expected, no excess
mortality is found
De Stefano and Leone nghtly state that one of the aims of
long-term prophylaxis should be to prevent not only mortality but
also morbidity from venous thromboembolism Although our study
was confined to mortality, anflcoagulation has its own nsk of
morbidity and mortality, which may become substanüal if
treatment is conanued for decades There is no evidence to date
that, in symptomless patients, the benefits of anticoagulation on
morbidity and mortality outweigh the nsk of this treatment Until
such evidence is available, we adhere to the pnnaple of "m dubio,
abstme"
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Hypotension with midazolam and fentanyl
in the newborn
SlR,—Midazolam, a water-soluble benzodiazepine with a shorter
ehmination half-hfe than diazepam, has been proposed for sedation
in children1 and the newborn who need surgery or intensive care
We report hypotension in six babies with respiratory distress
syndrome who were given midazolam in the first 12-36 hours of life
for sedanon Direct or rndirect blood pressure (BP) was recorded
Patient l received an intravenous Infusion of l μg/kg/h fentanyl
dunng the first 24 hours of life Because sedation was inadequate,
fentanyl was stopped and unmediately replaced by a 60 gg/kg/h
midazolam Infusion BP, which was already unstable (40/20 mm
Hg), decreased 5 h later to 34/13 mm Hg, and heart rate feil from
134 to 115/rmn Echocardiography showed poor myocardial
contracnhty Midazolam was stopped and dobutamine was
imnated BP feil further and remained unmeasurable by extemal
osallometry for l h Flumazeml, a benzodiazepine antagomst, was
admimstered However, systolic BP remained under 40 mm Hg and
heart rate under 120/rmn for another 5 h
Patient 2 received an intravenous bolus of l 5 μg/kg fentanyl and
5 h later a single intravenous bolus of 200 μg/kg midazolam was
admimstered BP had been unstable l h after midazolam BP
suddenly feil to 38/22 with a pulse of 110 and remained low for 7 h,
despite dopamine and plasma
